Navigation Links
Nfocus Neuromedical Announces US Clearance of Unique Guiding Catheter with Uni-body Internal Skeleton
Date:8/18/2009

PALO ALTO, Calif., Aug. 18 /PRNewswire/ -- Nfocus Neuromedical Inc. announced today that the Food & Drug Administration has cleared its novel guiding catheter, the Echo(TM) Distal Access Guiding Catheter, for marketing in the US.

"Nfocus works closely with key clinical opinion leaders to direct all of our design and development projects, and the Echo is our latest success story," said President and CEO Martin Dieck. "Our advisors identified the need for a guiding catheter with improved performance and our team has responded with Echo."

The Echo(TM) Distal Access Guiding Catheter has been cleared by the FDA for introduction of interventional and/or diagnostic devices in peripheral, coronary and neurovascular vessels. A high-quality guiding catheter is required in today's advanced and complex endovascular procedures to assist in reaching the target vessel with stents and other operative devices. The guiding catheter must be atraumatic and flexible within the distant and smaller target vessel - yet provide stable and firm support in the larger vessels where the device enters the body.

"The Echo is a stable platform for placing today's most advanced interventional devices and its unique construction gives it the ability to maintain a round lumen to enable endovascular procedures in very far-reaching vessel locations," continued Mr. Dieck.

"Combined with Echo's earlier CE Mark approval, the US FDA clearance gives Nfocus the ability to enter the top end of interventional guiding catheter markets worldwide. Endovascular surgeons and interventional neuroradiologists will appreciate the supple distal end which resists ovalizing of the lumen and the exceptional support of the proximal section - both produced by the unique catheter skeleton."

About Nfocus Neuromedical Inc.

Nfocus is positioning itself to be the world-wide leader in the development of next-generation endovascular neurosurgery solutions (surgery through less-invasive catheter devices) . Backed by premier venture investors, the Company is developing revolutionary systems to treat neurovascular disease - including brain aneurysms - which are simple, safe, cost-effective and curative.

To learn more about the Nfocus Neuromedical development programs focused on providing faster, simpler and more permanent treatment of vascular diseases of the brain and spine, please visit the Nfocus website: www.nfocusneuro.com.

For more information about aneurysms and hemorrhagic stroke see: www.strokeassociation.org and www.snisonline.org


'/>"/>
SOURCE Nfocus Neuromedical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nfocus Neuromedical Receives CE Mark for the CardioVasc(TM) Stent-Graft and Delivery System
2. Nfocus Neuromedical Announces Acquisition of StarFire Medical
3. Nfocus Neuromedical Elects Eric P. Milledge Chairman of Board
4. National Healthcare Providers Select onFocus epm(TM) To Help Ensure Success on Financial and Strategic Objectives
5. Nfocus Neuromedical Announces European Approval for Novel Guiding Catheter at Society of NeuroInterventional Surgery
6. Nfocus Neuromedical Obtains CE Approval for New Vascular Reconstruction Device
7. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
8. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
9. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
10. HEI, Inc. Announces Sale of RFID Division Assets
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... The threat of nuclear warfare has ... a company involved in the underground testing of nuclear weapons. Years later, when her ... Workers of the Cold War Nuclear Testing,” Clayton exposes the critical decisions made by ...
(Date:2/27/2017)... ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. – ... disclosed that despite scientific studies, the Center for Disease Control ( CDC ) and ... . Kenneth B. Liegner, M.D. has compiled into a single volume a compelling ...
(Date:2/27/2017)... ... 2017 , ... New Jersey ranks among the top five states in the ... need for advanced services is growing. , Project WE vs C is a ... with their non-profit partners in their fight against cancer and in support of their ...
(Date:2/26/2017)... ... February 26, 2017 , ... LatitudeC Baby Products, an ... announced it would be offering some it’s exclusive product line to the public ... and unique baby clothing/feeding products, will team up with AMAZON to distribute a ...
(Date:2/26/2017)... Florida (PRWEB) , ... February 26, 2017 , ... ... of Parkinson’s disease (PD) in persons with a specific LRRK2 mutation, according to ... Congress. , Previous studies have provided evidence of a link between pesticides and ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Feb. 23, 2017  Directors from Pharma To Market Pty Ltd ... joined forces, resulting in the founding of Pharma To Market Pte ... To Market are pleased to announce their expansion into ... Singapore . The company are delighted to appoint ... the Singapore based entity. Joelle brings with ...
(Date:2/24/2017)... 2017 Non-alcoholic steatohepataitis (NASH) Pipeline ... drugs being developed for the treatment of ... that are in various phases of development ... on novel pharmacologic drugs & regenerative medicines ... recombinant proteins and RNA-based therapeutics, but excludes ...
(Date:2/24/2017)... , Feb 24, 2017 ... Committee,s proposal for a new Board of Directors that ... The 2016-2017 Nomination Committee comprises representatives of the company,s ... quarter of 2016 who have accepted a seat on ... The composition of the 2016-2017 Nomination Committee was as ...
Breaking Medicine Technology: